Market Place
Sourcing Support
InvestmentPitch Media Video Discusses Resverlogix & Focus Apabetalone’s Future
30 Sep 2022 //
GLOBENEWSWIRE
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
28 Sep 2022 //
GLOBENEWSWIRE
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit
22 Aug 2022 //
GLOBENEWSWIRE
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders
21 Jun 2022 //
GLOBENEWSWIRE
Resverlogix`s Research Data Highlights Safety of BD2-selective BET Inhibitors
08 Jun 2022 //
GLOBENEWSWIRE
Resverlogix Announces Type C Meeting with FDA for CORAL, PIII Study
09 May 2022 //
GLOBENEWSWIRE
Resverlogix Announces One-Year Extension of Debenture
19 Apr 2022 //
GLOBENEWSWIRE
Resverlogix expands Phase IIb apabetalone trial for Covid-19
18 Feb 2022 //
CLINICALTRIALSARENA
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First
17 Feb 2022 //
PRESS RELEASE
Resverlogix Commences Patient Enrollment and Dosing in a Phase 2b Trial
18 Jan 2022 //
GLOBENEWSWIRE
Resverlogix, Supreme Council of Arab-African Economy to Support Apabetalone
04 Nov 2021 //
RESVERLOGIX
Resverlogix In Active Discussions The Kingdom of Morocco’s Ministry of Health
01 Nov 2021 //
GLOBENEWSWIRE
Resverlogix to Participate in Leading Scientific Conferences
29 Oct 2021 //
GLOBENEWSWIRE
Resverlogix to initiate Covid-19 therapy trial in Canada
13 Oct 2021 //
CLINICALTRIALSARENA
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19
12 Oct 2021 //
GLOBENEWSWIRE
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone
12 Oct 2021 //
YAHOO
Resverlogix`s Apabetalone Meets Primary Endpoint in a PAH Pilot Study
08 Sep 2021 //
GLOBENEWSWIRE
Resverlogix Announces Management Change
06 Jul 2021 //
GLOBENEWSWIRE
Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch
03 Jun 2021 //
GLOBENEWSWIRE
Resverlogix’s Apabetalone Demonstrates a Medical First in Patients
27 Apr 2021 //
GLOBENEWSWIRE
Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19)
22 Dec 2020 //
GLOBENEWSWIRE
Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders
22 Dec 2020 //
GLOBENEWSWIRE
Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2
22 Dec 2020 //
RUTERS
Resverlogix Announces Voting Results from the 2020 Meeting
22 Dec 2020 //
GLOBENEWSWIRE
Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection
02 Nov 2020 //
GLOBENEWSWIRE
Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation
09 Jun 2020 //
GLOBENEWSWIRE
RESVERLOGIX PLANS COVID-19 CLINICAL TRIAL PROGRAM LAUNCH
01 Jun 2020 //
PRESS RELEASE
Resverlogix Announces Publication of Key Apabetalone Study BETonMACE
30 Mar 2020 //
GLOBENEWSWIRE
Resverlogix Invites Collab for use of Apabetalone in Trials & Studies to Combat
23 Mar 2020 //
YAHOO
